Corcept submits NDA for relacorilant to treat Cushing's syndrome

CORCEPT THERAPEUTICS INC

NDA based on positive pivotal GRACE trial, Phase 3 GRADIENT, long-term extension and Phase 2 studies.
No drug-induced adrenal insufficiency, hypokalemia, QT prolongation, or progesterone receptor effects seen.
CEO Joseph Belanoff states relacorilant has potential to become standard of care for hypercortisolism.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.